Park Ha Biological Technology (BYAH) Cash & Equivalents (2023 - 2026)

Park Ha Biological Technology has reported Cash & Equivalents for 4 years, with the latest figure at $627851.0 in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 53.54% year-over-year to $627851.0 in Q2 2026; TTM through Apr 2026 was $627851.0, a 53.54% decrease from a year earlier, with the FY2025 full-year figure at $3.8 million, up 591.82% from the prior year.
• Cash & Equivalents was $627851.0 for Q2 2026 at Park Ha Biological Technology, down from $3.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $3.8 million in Q4 2025, with the low at $547498.0 in Q4 2024.
• Average Cash & Equivalents over 4 years is $1.5 million, with a median of $1.0 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents soared 591.82% in 2025, then slumped 53.54% in 2026.
• Over 4 years, Cash & Equivalents stood at $1.0 million in 2023, then sank by 47.03% to $547498.0 in 2024, then jumped by 591.82% to $3.8 million in 2025, then slumped by 83.42% to $627851.0 in 2026.
• The last three Cash & Equivalents figures came in at $627851.0 (Q2 2026), $3.8 million (Q4 2025), and $1.4 million (Q2 2025), per Business Quant data.